Shares of Seres Therapeutics Inc. (NASDAQ:MCRB) traded down 5.8% during trading on Friday . The stock traded as low as $11.05 and last traded at $11.13, with a volume of 659,216 shares changing hands. The stock had previously closed at $11.82.

Several analysts have recently commented on the stock. FBR & Co reissued a “buy” rating on shares of Seres Therapeutics in a research note on Monday, May 2nd. Canaccord Genuity reissued a “buy” rating on shares of Seres Therapeutics in a research note on Sunday, May 29th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research note on Monday, June 13th. Zacks Investment Research lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 18th. Finally, Leerink Swann restated a “buy” rating and issued a $12.00 price objective on shares of Seres Therapeutics in a report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $31.57.

The stock’s market cap is $444.62 million. The firm has a 50 day moving average of $22.79 and a 200-day moving average of $26.42.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.24. The firm had revenue of $3 million for the quarter, compared to the consensus estimate of $4.20 million. During the same period in the previous year, the firm earned ($1.45) EPS. The company’s quarterly revenue was up NaN% on a year-over-year basis. Equities research analysts anticipate that Seres Therapeutics Inc. will post ($2.19) EPS for the current year.

In other news, CEO Roger Pomerantz sold 9,801 shares of the business’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $30.00, for a total value of $294,030.00. Following the completion of the transaction, the chief executive officer now directly owns 193,493 shares in the company, valued at approximately $5,804,790. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP John G. Aunins sold 9,390 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $27.23, for a total transaction of $255,689.70. Following the completion of the transaction, the executive vice president now owns 32,655 shares of the company’s stock, valued at $889,195.65. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Seres Therapeutics stock. Morgan Stanley increased its stake in shares of Seres Therapeutics Inc. (NASDAQ:MCRB) by 225.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,758 shares of the company’s stock after buying an additional 23,381 shares during the period. Morgan Stanley owned about 0.09% of Seres Therapeutics worth $1,185,000 as of its most recent filing with the SEC.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.